NRCC
NOTICE OF REGISTRATION CONFIRMATION EMAILED
04/18/2023
Back to search
Official data from USPTO
GENMET-VEC
Did you know this trademark is already registered in United States?
Before investing in name, identity, and promotion, validate collision risk and registration strategy to avoid wasting time and budget.
Active USPTO registrationType: CombinedOffice: United States
Risk and opportunity diagnosis
Executive reading for naming, filing, and monitoring decisions.
USPTO status
Active USPTO registration
Case type
Application and registration
Recorded events
17
Latest update
04/18/2023
Trademark type
Combined
Nice classes
5
Filing date
09/08/2021
Registration date
04/18/2023
Expiration date
-
Complete case details
Structured fields from the responsible authority and the official record.
Status date
04/18/2023
Last transaction
04/18/2023
Responsible office
United States Patent and Trademark Office
Status code
700
Official register
Principal Register
Filing basis
Intent to use
First use anywhere
05/10/2022
First use in commerce
06/20/2022
Drawing code
3
Owner type
16
Owner location
Guangdong Province, CN
Examiner
LATTUCA, FRANK
Law office
L90
Current location
PUBLICATION AND ISSUE SECTION
Mark description
The mark consists of the word "Genmet-Vec" in standard lettering on the left and four Chinese characters in horizontal arrangement on the right.
Holders and representatives
Holders
Guangzhou Sinogen Pharmaceutical Co., Ltd.
Representatives
Yue (Robert) Xu APEX ATTORNEYS AT LAW, LLP
Technical classification
Nice Classes
Class 5
Vienna Codes
No Vienna codes available.
Goods and services
Class 5
Anti-cancer preparations; Pharmaceutical products for the treatment of cancer; Biological preparations for the treatment of cancer; Pharmaceutical products for the prevention and treatment of cancer; Pharmaceutical products for the treatment of viral and infectious diseasesfor the treatment of cancer; Tumor suppressing agents; Protein arrays for diagnosing cancer; Radiopharmaceutical imaging and detection agents for diagnosing and monitoring cancer; Human vaccine preparations; Antibiotics for human use; Dietary supplements for human consumption; Diagnostic preparations for medical purposes for detecting the presence of malignantinflammatory and autoimmune disorders and conditions and tissue trauma in humans; Radioactive substances for medical purposes; Gases for medical and dental use; Gases and gas mixtures for medical imaging use; Cartridges sold pre-filled with gases and gas mixtures for medical use; Disinfectants; Bacteriological culture mediums; Dietetic foods adapted for medical purposes; Surgical dressings; All containing in whole or significant partgene therapy substances
Publications
History of USPTO decisions and trademark events.
17 publications found
R.PR
REGISTERED-PRINCIPAL REGISTER
04/18/2023
SUNA
NOTICE OF ACCEPTANCE OF STATEMENT OF USE E-MAILED
03/14/2023
CNPR
ALLOWED PRINCIPAL REGISTER - SOU ACCEPTED
03/12/2023
SUPC
STATEMENT OF USE PROCESSING COMPLETE
03/10/2023
AITU
CASE ASSIGNED TO INTENT TO USE PARALEGAL
03/10/2023
IUAF
USE AMENDMENT FILED
02/22/2023
EISU
TEAS STATEMENT OF USE RECEIVED
02/22/2023
NOAM
NOA E-MAILED - SOU REQUIRED FROM APPLICANT
09/13/2022
NPUB
OFFICIAL GAZETTE PUBLICATION CONFIRMATION E-MAILED
07/19/2022
PUBO
PUBLISHED FOR OPPOSITION
07/19/2022
NONP
NOTIFICATION OF NOTICE OF PUBLICATION E-MAILED
06/29/2022
CNSA
APPROVED FOR PUB - PRINCIPAL REGISTER
06/12/2022
DOCK
ASSIGNED TO EXAMINER
06/12/2022
MDSC
NOTICE OF DESIGN SEARCH CODE E-MAILED
10/19/2021
NWOS
NEW APPLICATION OFFICE SUPPLIED DATA ENTERED
10/18/2021
NWAP
NEW APPLICATION ENTERED
09/11/2021
Continuous trademark protection
Get notified about every new filing that threatens GENMET-VEC or your mark.
Professional 24-month watch service: we monitor USPTO for you and alert you in time to oppose — before conflicts become losses.